

## MEDIA RELEASE

### HypoPet Enters Into an Agreement with a Major Animal Health Company

Zürich Switzerland 2<sup>nd</sup> of October 2019 – HypoPet AG reported today that it has executed a contract with a top-tier global animal health company.

HypoPet AG announced Wednesday the signing of an agreement with a major animal health company. The execution of this agreement is another important step in the companies publically stated business plan, which is to form strategic alliances with leading global companies to advance its technology, projects and pipeline. It is the third deal in the increasingly lucrative animal health sector announced by HypoPet since its founding. The others being license deals for their HypoCat vaccine for cat allergy suffered by humans and a therapeutic vaccine for treating canine atopic dermatitis.

Dr Gary T Jennings, CEO of HypoPet AG commented, “We are extremely pleased to have signed this agreement with a leading animal health company and are looking forward to the collaboration and accessing their formidable research and development capabilities. We appreciate the innovative spirit and foresight of our new partner and view this agreement as further endorsement of the potential of our technology and the quality of the science performed by our R&D team”.

#### For further information, please contact

HypoPet AG Moussonstrasse 2 CH-8044 Zürich, Switzerland  
Gary Jennings, PhD  
CEO  
gary.jennings@hypopet.ch  
Website [www.hypopet.ch](http://www.hypopet.ch)

#### About HypoPet AG

HypoPet AG is a privately held Swiss biotechnology company based in Zürich, Switzerland that was formed as a spin-off company from the University of Zürich in 2013. HypoPet is developing therapeutic virus-like particle (VLP) vaccines (VLP) designed to instruct the patient’s immune system to produce antibodies which specifically neutralize disease-associated molecules within the animal and thereby modulate chronic disease processes<sup>2</sup>. Taking advantage of the flexibility of the platform VLP vaccine technology, HypoPet is establishing a high-quality pipeline filled with promising new animal drug candidates that address major unmet needs in veterinary medicine. The remarkable advances achieved in the treatment of chronic human diseases by the use of monoclonal antibodies can now be made available to our pets by the use of pet-specific vaccines. HypoPet is leveraging the experience of monoclonal antibodies, which have already achieved proof of principle (efficacy, safety & commercial) in humans and in some cases in companion animals. HypoPet’s VLP platforms are also being used to develop vaccines against infectious diseases.

#### Forward looking statement

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of HypoPet AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.